Digital Cognitive Testing Uncovers Hidden Impairment in MS Digital Cognitive Testing Uncovers Hidden Impairment in MS
A computerized neuropsychological screen is taking the'guesswork'out of documenting disease impact and progression on cognitive outcomes in patients with multiple sclerosis, researchers say.Medscape Medical News
Acute appendicitis is the most common surgical emergency and becomes serious when it perforates. The principal presenting complaint of patients with acute appendicitis is abdominal pain. The diagnosis may be missed in patients with neurological disorders- in this case multiple sclerosis (MS) and quadriplegia-who do not complain of pain. There are limited research and practice guidelines for patients with chronic neurodegenerative disorders with acute abdomen.
Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.1 An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.
Increasing evidence links the microbiome's composition with several psychiatric and neurological diseases, including autism, schizophrenia, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease and multiple sclerosis – Mark Greener investigates.
The cystine/glutamate antiporter (xc-) has been implicated in several neurological disorders and, specifically, in multiple sclerosis (MS) as a mediator of glutamate excitotoxicity and proinflammatory immune r...
Benign multiple sclerosis (BMS) is a controversial term that has been used for MS patients with minimal disability decades after disease onset. Herein, we evaluated disease status after 20 years in a Western Australian cohort defined as BMS based on an Expanded Disability Status Scale (EDSS) score ≤ 3.0 at 10 years from onset.
This article summarises its dosing and monitoring requirements, efficacy in the CLARITY trial and place in therapy.
Publication date: Available online 22 February 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Franziska Di Pauli, Markus Reindl, Thomas Berger Acquired demyelinating CNS syndromes include a broad spectrum of clinical phenotypes and different entities can overlap. Therefore, differential diagnosis is still challenging. A humoral immune reaction against myelin oligodendrocyte glycoprotein (MOG) is present in a subgroup of these patients, particularly in children. Anti-MOG antibodies indicate a non-multiple sclerosis disease course. Indeed, early publications have suggested that anti-MOG antibodies argue for...
No abstract available
Conclusions: There have been great advances in therapeutic research in MS. However, the stratification of patients according to their prognosis and predictive outcomes in response to treatment is still in its infancy. The many facets of MS make it difficult to piece all the data together into one cohesive conclusion for the individual patient. The visual system, with our ability to assess both structure and function, offers a promising opportunity to study both pathophysiologic mechanisms and novel therapies.
Conclusions: This review highlights our current knowledge of the underlying disease mechanisms in MS, explores the inflammatory and neurodegenerative consequences of tissue damage, and examines physiologic factors that contribute to bioenergetic homeostasis within the CNS of affected patients.